Neurocetam Special Precautions

Piracetam should not be given to patients with hepatic dysfunction or severe renal impairment. Dosage reductions are recommended for patients with lesser degrees of renal impairment. Therapy with piracetam should not be withdrawn abruptly.
Piracetam is reported to inhibit platelet aggregation and reduce blood viscosity at high doses.
Neurocetam Injection: Piracetam is eliminated via the renal route; care should thus be taken in cases of renal insufficiency. In these patients, the increased half-life is inversely related to creatinine clearance. The table shows the dose reductions corresponding to creatinine clearance <60 mL/min.

Click on icon to see table/diagram/image

Abrupt discontinuation of treatment should be avoided in myoclonic patients, as this may induce myoclonic or generalised seizures.
Use in pregnancy & lactation: Reproduction studies in animals have not identified any risk to the foetus. No studies in pregnant women have, however, been reported. Thus, as for all medications, the physician should evaluate the potential benefits of treatment, especially during the 1st trimester and during lactation.